Samuraciclib is under clinical development by Carrick Therapeutics and currently in Phase II for Breast Cancer. According to GlobalData, Phase II drugs for Breast Cancer have a 34% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Samuraciclib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Samuraciclib overview

Samuraciclib (CT-7001) is under development for the treatment of triple negative breast cancer, metastatic or locally advanced HR+ and HER2- breast cancer, colorectal cancer, ovarian cancer, prostate cancer, acute myeloid leukemia and small-cell lung cancer. It is administered through the oral route. The drug candidate acts by targeting cyclin-dependent kinase 7 (CDK7).

Carrick Therapeutics overview

Carrick Therapeutics is a biopharmaceutical company that focuses on the research and development of cancer therapies. The company develops drugs that target the molecular pathways of the most aggressive and resistant forms of cancer. In addition, the company strives to advance its programs by comprehending the cancer-causing mechanisms and combining them with the latest technologies to identify treatments. It works in collaboration with a cancer research charity, Cancer Research UK, and academic institutions such as Cambridge University, Oxford University, and Imperial College, to discover and develop cancer medicines. The company has a presence in Ireland and the UK. Carrick Therapeutics is headquartered in Dublin, Ireland.

For a complete picture of Samuraciclib’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.